Page 33 - P4403.14-V110 November OTC Magazine 2025 NI
P. 33

GASTRO  33



                                               TAKE





                                      ACTION







                                              AGAINST




                     Up To            HEARTBURN

                    24%
                     POR





















                                   UP TO

                               24hr


                                RELIEF                        Product           Size  Buying   RRP  Trade    POR    Pip Code
                                                                                     Price/
                                                                                              Offer
                                                                                                   %
                                                                                     Single
                                                                                               %
                                                              PERRIGO
                                                               Perrigo Esomeprozole 14s   14  £3.37  £6.99  5%  42% 4188355
                                                                Perrigo Esomeprozole 7s   7  £1.92  £3.99  6%  42% 4188348
                   UP TO 24HR RELIEF FROM

                   HEARTBURN & ACID REFLUX






                   Perrigo Heartburn and Acid Reflux Control 20 mg Gastro Resistant Capsules (GSL) contain esomeprazole (as magnesium dihydrate). For
                   the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Adults 18 years and over: One capsule per day.
                   It may be necessary to take the capsules for 2-3 consecutive days to achieve improvement of symptoms. The duration of treatment is up to 2
                   weeks. Contraindications: known hypersensitivity to esomeprazole, substituted benzimidazoles or to any of the excipients, concomitant use
                   with nelfinavir. Caution: history of gastric ulcer or GI surgery, suspected gastric ulcer or malignancy, jaundice, severe liver disease, or aged over
                   55 years with new or changed symptoms, increased risk of GI infection. Interference with lab tests for neuroendocrine tumours. This medicine
                   contains 0.0018mg benzoic acid in each capsule. Pregnancy and breast-feeding: avoid in pregnancy and do not use during breast-feeding.
                   Interactions: atazanavir, ritonavir, saquinavir, methotrexate, tacrolimus, digoxin, warfarin, phenytoin, citalopram, imipramine, clomipramine,
                   diazepam, clopidogrel. Side effects: hypersensitivity reactions e.g. angioedema & anaphylactic reaction, agranulocytosis, thrombocytopenia,
                   leukopenia,  pancytopenia,  hepatic  failure,  erythema  multiforme,  Stevens-Johnson  syndrome,  toxic  epidermal  necrolysis  (TEN),  subacute
                   cutaneous lupus erythematosus (SCLE), headache, abdominal pain, constipation, diarrhoea, flatulence, nausea, vomiting, fundic gland polyps
                   (benign), bronchospasm. PL 16028/0166. MAH: Galpharm Healthcare Limited, Wrafton, Braunton, Devon, EX33 2DL, UK. Date of preparation:
                   08/2021. RRP (ex. VAT): 7s £4.99,14s £8.99. MAT-9749







                                                                                                                 07/10/2025   16:58:54
         P4403.14-V110 November OTC Magazine 2025 NI.indd   33
         P4403.14-V110 November OTC Magazine 2025 NI.indd   33                                                   07/10/2025   16:58:54
   28   29   30   31   32   33   34   35   36   37   38